Press release
Migraine Drugs Market to Nearly Double to $23.7B by 2031, Growing at 10.3% CAGR Driven by Novel CGRP Inhibitors & Combination Therapies | Top Companies are Allergen, Eisai, Ltd., AstraZeneca plc
Migraine Drugs Market
According to DataM Intelligence has published a new research report on "Migraine Drugs Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.
Migraine drugs are pharmaceuticals formulated to relieve or prevent migraine headaches. They include triptans, CGRP inhibitors, NSAIDs, and preventive medications like beta-blockers. These treatments target pain pathways or prevent migraine triggers. Increasing migraine prevalence drives demand for innovative therapies. The market focuses on long-acting, fast-relief, and patient-friendly formulations.
📌 Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/migraine-drugs-market?rk
➣ Recent Developments:
✅ In July 2025, Amgen reported Phase II success for its oral CGRP inhibitor aimed at chronic migraine prevention. The therapy shows strong efficacy with once-daily dosing.
✅ In June 2025, Eli Lilly received expanded FDA approval for its migraine biologic covering adolescent patients. The indication broadens access to preventive treatment options.
✅ In May 2025, Pfizer and Biohaven launched a combination therapy program evaluating dual-pathway drugs for acute migraine relief. Early data highlights faster onset and improved patient outcomes.
📌 Get Customization in the report as per your requirements: https://datamintelligence.com/customize/migraine-drugs-market?rk
➣ Top Industry Players:
Allergen, Eisai, Ltd., AstraZeneca plc, Abbott Laboratories, Eisai Co., Ltd., Endo International Plc., GlaxoSmithKline Plc., Merck & Co., Inc., Pfizer Inc., and Johnson & Johnson among others.
📌 Buy Now & Get 30% OFF - (Grab 50% OFF on 2+ reports) @: https://www.datamintelligence.com/buy-now-page?report=migraine-drugs-market?rk
➣ Market Segments:
By Type: Abortive Medicine, Preventive Medicine.
By Route of Administration: Oral, Injectable, Others.
By Distribution Channel: Hospital-Based Pharmacies, Retail Pharmacies, Online Pharmacies.
📌 Have any Enquiry of This Report @ https://www.datamintelligence.com/enquiry/migraine-drugs-market?rk
☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.
✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring
☛ Get 2-Day Free Trial + 50% OFF DataM Subscription@ https://www.datamintelligence.com/reports-subscription?rk
Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Migraine Drugs Market to Nearly Double to $23.7B by 2031, Growing at 10.3% CAGR Driven by Novel CGRP Inhibitors & Combination Therapies | Top Companies are Allergen, Eisai, Ltd., AstraZeneca plc here
News-ID: 4310839 • Views: …
More Releases from DataM Intelligence 4market Research LLP
Solar PV Distributed Energy Generation Market to Witness Accelerated Growth as T …
Austin, Texas, April 29, 2026: DataM Intelligence has released its latest analysis on the Solar PV Distributed Energy Generation Market, highlighting how electrification trends, grid modernization initiatives and rising energy security concerns are reshaping global demand dynamics.
The Solar PV Distributed Energy Generation Market is expected to grow from approximately USD 538.2 billion in 2025 to around USD 884.8 billion by 2033, registering a CAGR of about 6.4% during the forecast…
Lithium Chemicals Market to Accelerate as Electrification, Charging Infrastructu …
Austin, Texas, April 29, 2026: DataM Intelligence has released its latest analysis on the Lithium Chemicals Market, highlighting strong growth momentum driven by accelerating electrification, expansion of energy storage systems and rising demand for critical battery materials. The Lithium Chemicals Market was valued at US$ 8.95 billion in 2025 and is expected to reach US$ 22.79 billion in 2033, growing at a CAGR of 12.40% during the forecast period (2026-2033).…
Data Center Construction Market to See Strong Demand as Technology Convergence a …
The Global Data Center Construction Market reached USD 261.31 billion in 2025 and is expected to reach USD 662.71 billion by 2033, growing at a CAGR of 9.8% during the forecast period 2026-2033 as global demand for high-performance computing infrastructure accelerates with the rapid expansion of cloud computing, artificial intelligence (AI), big data analytics, and digital transformation initiatives across industries.
Growth is supported by surging demand across key application areas such…
Automotive ABS System Market to See Strong Demand as Technology Convergence and …
The Global Automotive ABS System Market reached US$ 36.56 billion in 2025 and is expected to reach US$ 65.16 billion by 2033, growing with a CAGR of 7.5 % during the forecast period 2026-2033
DataM Intelligence has released its latest analysis on the Automotive ABS System Market, highlighting how autonomy, safety mandates, and next-generation mobility platforms are accelerating demand across global automotive ecosystems. According to the report, the market is…
More Releases for Migraine
Leading Growth Driver in the Migraine Market Share in 2025: Rising Prevalence Of …
What Market Share dynamics are playing a key role in accelerating the growth of the migraine Market Share?
The migraine Market Share is projected to grow, driven by the rising occurrence of migraines. Migraines, a kind of headache that typically affects one side of the brain and causes intense, throbbing pain or a pulsing sensation, can be managed and relief can be provided via proper treatment. This treatment paves the way…
Emerging Acute Migraine Treatment Market Trend 2025-2034: Innovative CGRP Recept …
How Is the Acute Migraine Treatment Market Projected to Grow, and What Is Its Market Size?
The market size for acute migraine treatment has witnessed substantial growth in the past few years. Forecasts expect it to expand from $2.6 billion in 2024 to $2.91 billion in 2025, boasting a compound annual growth rate (CAGR) of 11.6%. Factors contributing to this growth in the historical period include the rising incidence of migraines,…
Key Influencer in the Migraine Market 2025: Rising Prevalence Of Migraine Drives …
"What Is the Forecasted Market Size and Growth Rate for the Migraine Market?
The migraine market is projected to grow steadily from $1.93 billion in 2024 to $1.97 billion in 2025, at a CAGR of 2.2%. This growth is attributed to the rising prevalence of migraines, growing awareness of treatment options, government initiatives, increased alcohol consumption, and lifestyle changes.
Migraine Market: Expected to grow to $2.25 billion by 2029 at a CAGR…
How Big is Migraine Drugs Market?
In 2022, the Global Migraine Drugs Market soared to USD 10,972.1 million, marking a significant milestone. Projections indicate a promising trajectory, with expectations set for substantial growth, potentially reaching USD 26,618.96 million by 2031. Forecasts for the period between 2024 and 2031 suggest a robust Compound Annual Growth Rate (CAGR) of 12.1% for the migraine drugs market.
The objectives outlined in the report are multifaceted and aimed at offering a comprehensive…
Migraine Therapeutics Market - Relieve the Burden: Empowering Lives through Migr …
Newark, New Castle, USA - new report, titled Migraine Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Migraine Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Migraine Therapeutics market. The report offers an overview of the market, which…
Rise in Prevalence of Migraine Drives the Migraine Drugs Market | Outlook 2025
Migraine is characterized by a recurrent throbbing headache, which affects only one side of the head. It is accompanied by vomiting, nausea and even altered vision in some cases.
The increase in the prevalence of migraine, the rapid increase in the female population and the increased awareness among patients for the treatment and prevention of migraine are driving the growth of the global market for anti-migraine drugs.
Get Access to TOC /…
